Welcome to our dedicated page for Alps Group news (Ticker: ALPS), a resource for investors and traders seeking the latest updates and insights on Alps Group stock.
News and press releases referencing the symbol ALPS cover two distinct corporate contexts. More recent communications describe ALPS Group Inc, a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine. Earlier news items under the same symbol relate to Alpine Summit Energy Partners, Inc., a U.S.-based company that operated and developed oil and gas assets.
For ALPS Group Inc, news updates highlight its role as the parent company of Alps Life Sciences Inc, an integrated biotechnology platform that combines research and development, medical services, and wellness solutions of advanced therapies. Coverage includes the completion of its business combination with Globalink Investment Inc, its listing of ordinary shares on the Nasdaq Stock Market under the ticker ALPS, and leadership developments such as the appointment of a Chief Financial Officer to oversee financial strategy, budgeting, audit, tax compliance, and risk management.
Historical news tied to Alpine Summit Energy Partners, Inc. focuses on activities in the oil and gas sector. These items discuss operating and developing oil and gas assets, financial and operating results, force majeure events affecting South Texas operations, strategic asset sale processes, board changes, share issuances, and the commencement of a voluntary Chapter 11 process in the U.S. Bankruptcy Court for the Southern District of Texas. Such releases also reference trading on the TSX Venture Exchange and NASDAQ under the ALPS-related symbols during that period.
Readers using this news feed for ALPS can therefore expect a mix of biotechnology and healthcare platform developments associated with ALPS Group Inc and historical energy-sector announcements associated with Alpine Summit Energy Partners, Inc. Reviewing publication dates and company names in each article can help distinguish between the biotechnology-focused ALPS Group Inc and the earlier oil and gas company that previously used the ALPS ticker.
Alps Group (NASDAQ:ALPS) published a peer-reviewed case series (Feb 2026) reporting safety and tolerability data from nine patients who received autologous NK cell infusions produced with its in-house culture protocol.
The study (NMRR ID 25-00333-MUM) and Malaysian patent application PI2025002484 describe an antibody-free, cost-efficient method for large-scale NK cell production and aim to support future clinical trials.
Alps Group (NASDAQ:ALPS) announced potential expansion of its exosome pipeline beyond CELESOME(+) following publication of a peer‑reviewed retrospective clinical case series on nebulized hUCMSC‑derived exosomes in patients with asthma and/or COPD.
The published series reports observed improvements in pulmonary function, stable inflammatory markers, and no significant adverse effects after weekly 30‑minute nebulized dosing for five weeks (1 ml exosome solution mixed with 5 ml saline).
Alps Group (NASDAQ: ALPS) appointed Cheing Lye-Ping (Penny) as Chief Financial Officer, effective January 5, 2026. Ms. Cheing will lead financial strategy, budgeting, planning and analysis, audit, tax compliance, risk management, accounting, and treasury across Alps Group and subsidiaries. She brings over 30 years of finance and accounting experience, including CFO and CEO roles in property development and investment firms, and early-career audit experience at Arthur Andersen. Ms. Cheing holds a Bachelor in Accountancy, an MBA, is a Chartered Accountant with the Malaysian Institute of Accountants, and a Fellow of CPA Australia.
Alps Group Inc (NASDAQ: ALPS) completed its business combination with Globalink Investment Inc. and began trading on Nasdaq on October 31, 2025, with warrants trading OTC under ALPWF. The combined company has an estimated enterprise value of ~US$1.6 billion and will be headquartered in Kuala Lumpur, Malaysia.
Leadership carries forward from Alps Holdco, with Dr. Tham Seng Kong serving as CEO and chairman. A concurrent PIPE raised approximately US$3,107,875 for roughly 310,788 ordinary shares to support growth and working capital. The transaction used a two-step merger (Redomestication Merger and Acquisition Merger) and was approved by Globalink stockholders on October 7, 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.